SB 525334

CAS No. 356559-20-1

SB 525334( SB-525334 | SB525334 )

Catalog No. M14224 CAS No. 356559-20-1

SB 525334 is a potent and selective inhibitor of TGF-β1 receptor (ALK5) inhibitor with IC50 of 14,5 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 48 In Stock
10MG 80 In Stock
25MG 160 In Stock
50MG 268 In Stock
100MG 427 In Stock
200MG 502 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SB 525334
  • Note
    Research use only, not for human use.
  • Brief Description
    SB 525334 is a potent and selective inhibitor of TGF-β1 receptor (ALK5) inhibitor with IC50 of 14,5 nM.
  • Description
    SB 525334 is a potent and selective inhibitor of TGF-β1 receptor (ALK5) inhibitor with IC50 of 14,5 nM, 4-fold less potent against ALK4 and inactive for ALK2, ALK3, and ALK6 (IC50>10 uM); blocks TGFβ1-induced phosphorylation and nuclear translocation of Smad2/3 in renal proximal tubule cells and inhibits TGFβ1-induced increases in PAI-1 and procollagen α1 mRNA expression in A498 renal epithelial carcinoma cells at 1 uM; significantly inhibits PAN-induced proteinuria in rat model of nephritis-induced renal fibrosis.
  • In Vitro
    SB525334 (1 μM; for 15 minutes before stimulating with 0.625 ng/ml of TGF-β1, assesses after 6 days) inhibits TGF-β1-mediated proliferation of familial idiopathic pulmonary arterial hypertension (iPAH) pulmonary artery smooth muscle cells (PASMCs) at an IC50 of 295 nM . Cell Proliferation AssayCell Line:PASMC cells Concentration:1 μM Incubation Time:Pre-incubated for 15 minutes (before stimulating with 0.625 ng/ml of TGF-β1), assessed after 6 days Result:Inhibited TGF-β1-mediated proliferation of familial iPAH PASMCs at an IC50 of 295 nM.
  • In Vivo
    SB525334 (3-30 mg/kg; p.o.; daily from days 17 to 35) significantly reverses pulmonary arterial pressure in a rat model of pulmonary arterial hypertension (PAH). Animal Model:Adult male Sprague-Dawley rats (MCT rat model of pulmonary hypertension)Dosage:3, 30 mg/kg Administration:Oral administration; daily from days 17 to 35 Result:Reduced the proportion of fully muscularized vessels to 28% at 3 mg/kg and returned fully muscularized vessel distribution beyond that seen at day 17 and approaching the phenotype observed in saline-exposed controls at 30 mg/kg.
  • Synonyms
    SB-525334 | SB525334
  • Pathway
    TGF-beta/Smad
  • Target
    TGFBR
  • Recptor
    TGFβR1(ALK5)|ALK5|ALK4
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    356559-20-1
  • Formula Weight
    343.4249
  • Molecular Formula
    C21H21N5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 46 mg/mL
  • SMILES
    CC1=CC=CC(C2=C(C3=CC=C4N=CC=NC4=C3)N=C(C(C)(C)C)N2)=N1
  • Chemical Name
    Quinoxaline, 6-[2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Grygielko ET, et al. J Pharmacol Exp Ther. 2005 Jun;313(3):943-51. 2. Laping NJ, et al. Clin Cancer Res. 2007 May 15;13(10):3087-99. 3. Thomas M, et al. Am J Pathol. 2009 Feb;174(2):380-9. 4. Kim YJ, et al. Anticancer Res. 2012 Mar;32(3):799-806.
molnova catalog
related products
  • Disitertide

    Disitertide (P144) is a TGF-β1 antagonist peptide.

  • Epimedin C

    Epimedin C was metabolized via desugarization, dehydrogenation, hydrogenation, dehydroxylation, hydroxylation, demethylation and glucuronidation pathways in vivo.

  • LY2157299

    LY2157299 (Galunisertib) is a potent, specific inhibitor of TGF-β receptor I kinase ((TGF-βRI) with IC50 of 56 nM.